There are two types of infectious vaccinia virus particles: intracellular naked virions and extracellular enveloped virions (EEV). To determine the biological role of the enveloped form of vaccinia virus, we produced and characterized a mutant that is defective in EEV formation. The strategy involved replacement by homologous recombination of the gene F13L, encoding a 37,000-Da protein (VP37) that is specific for the outer envelope of EEV, with a selectable antibiotic resistance marker, the Escherichia coli gpt gene. Initial experiments, however, suggested that such a mutation was lethal or prevented plaque formation. By employing a protocol consisting of high-multiplicity passages of intracellular virus from the transfected cells and then limiting dilution cloning, we succeeded in isolating the desired mutant, which was defective in production of plaques and extracellular virus but made normal amounts of intracellular naked virions. Electron microscopic examination indicated that the mutant virus particles, unlike wild type, were neither wrapped with Golgiderived membranes nor associated with the cell surface. The absence of VP37 did not prevent the transport of the viral hemagglutinin to the plasma membrane but nevertheless abrogated both low-pH-and antibodymediated cell fusion. These results indicate that VP37 is required for EEV formation and also plays a critical role in the local cell-to-cell transmission of vaccinia virus, perhaps via enveloped virions attached to or released from the cell membrane. By contrast, a mutated virus with a deletion of the K4L open reading frame, which is a homolog of the VP37 gene, was not defective in formation of plaques or EEV.
Vaccinia virus, the representative member of the Poxviridae, has a complex replicative cycle that occurs in the cytoplasm of infected cells (reviewed in reference 20) . Late stages of virus assembly have been visualized by electron microscopy (19) , but the biochemical mechanisms and protein interactions involved in the process are not understood. Two related but morphologically and antigenically distinct forms of infectious vaccinia virions have been recognized (2) : intracellular naked virions (INV) and extracellular enveloped virions (EEV). The INV, which contain a complex core structure surrounded by a lipoprotein membrane, are more abundant and have been more thoroughly studied than the EEV, which have an additional envelope. The process leading to virus release involves wrapping of mature INV particles by two layers of Golgi-derived membranes and the subsequent fusion of the outer layer with the plasma membrane (15, 19, 25) . The major protein in the external envelope of EEV, VP37, has an apparent molecular mass of 37,000 Da (11, 22) and is encoded by vaccinia virus open reading frame F13L (13) . This protein contains bound palmitic acid and is localized in Golgi-derived membranes (12) .
EEV may be important in animal infections since antisera to inactivated INV do not neutralize EEV and fail to protect against a live virus challenge (1, 23, 33) . Conversely, antisera that neutralize EEV can protect animals from experimental infections. Antibody specific to EEV also inhibits the formation of comets in plaque assays of virus with a liquid overlay (2, 4) . The comets are tails composed of small secondary plaques derived from the larger primary plaques. The ability of anti-EEV antiserum to inhibit comet formation * Corresponding author.
indicates that long-distance spread of infectious virus in vitro is mediated by EEV. However, since INV are highly infectious, it seemed that isolation of virus mutants unable to generate extracellular virus would be possible. In this report, we describe the construction and characteristics of such a mutant.
MATERIALS AND METHODS
Cells and viruses. The IHD-J and IHD-W strains of vaccinia virus were kindly provided by S. Dales, University of Western Ontario, London, Ontario, Canada, and were routinely propagated and titered in green monkey kidney BSC-1 cells grown in minimal essential medium supplemented with 10% fetal calf serum. The plaque titers were determined after 2 days by staining with crystal violet. vRB10 mutant virus was also grown and titered in BSC-1 monolayers that were incubated for 5 to 7 days before staining.
Antibodies. Monoclonal antibody MAbC3 (27) , specific for the vaccinia virus 14,000-Da protein, and monoclonal antibody B2D10, specific for the virus hemagglutinin (HA) (16) xanthine guanine phosphoribosyl transferase (gpt) under the control of the vaccinia virus 7.5 promoter and with suitable restriction sites for the cloning of vaccinia virus sequences to direct insertion of the gpt cassette into the vaccinia genome is described elsewhere (3) . Sequences flanking genes F13L and K4L were amplified by polymerase chain reaction. The primers for the left flank of F13L were 5'-GCATATGCAT QCTTTGTTAAAATAGATA-3' (SphI site underlined) and 5'-CATTTTGCTCGAGCAGGTACCGATGCAA-3' (XhoI site underlined). The primers for the right flank of F13L were 5'-GAGAGAGCTCGGGTATCTAGCCACAGTA-3' (Sacl site underlined) and 5'-GCGCCCACAATGCATC TCTAGATATGTA-3' (NsiI site underlined). The primers for the left flank of K4L were 5'-TGAGTGCATGCTGTAT GTTCAATCTGGA-3' (SphI site underlined) and 5'-GCAT ACCTCGAGGAATAGTCTCTGTAATCA-3' (XhoI site underlined). The primers for the right flank of K4L were 5'-CTGCGATGAGCTCCAACCGGAAAAAGAAA-3' (Sacl site underlined) and 5'-TTGTCGAGCTCATTAGAATCTA CTACATTA-3' (SacI site underlined). After polymerase chain reaction amplification, the flanking gene sequences were inserted into unique restriction sites in the plasmid pGEM-gpt.
Isolation of recombinant viruses. Monolayers of CV-1 cells were infected with vaccinia virus IHD-J at a multiplicity of infection (MOI) of 0.05 and transfected with plasmids by the calcium phosphate technique, following standard protocols. Recombinant viruses were selected by three consecutive rounds of plaque purification in the presence of mycophenolic acid (9) . Subsequently, viruses were amplified by infection of cell monolayers, and the DNA was analyzed by Southern blot hybridization.
In the isolation of the deletion mutant vRB10, high-MOI passages were achieved by infecting BSC-1 cells in a 9-cm2 well with 200 ,ul of a crude IHD-J virus stock. At 48 h after infection, the cells were harvested, freeze-thawed three times to release the virus, and sonicated. A limit dilution cloning procedure was performed from this virus stock as follows. Serial dilutions (10-fold) were used to infect BSC-1 cells in 96-well trays. Twelve wells were infected with each dilution and were observed at 48 h after infection for the presence or absence of virus plaques. Wells with no virus plaques were selected, and the cells were scraped, freezethawed three times, and sonicated. Two-thirds of the material obtained from each well was used to infect BSC-1 cells in 24- conditions. To test whether F13L and K4L deletion mutants were obtained, the progeny virus was plaque purified three times in selection medium and then the DNA samples from several amplified plaques (Fig. 2 , upper part) were analyzed by restriction enzyme digestion and Southern blotting. The results indicated that the K4L gene had been successfully deleted from the viral genome of several clones (data not shown). However, there were no plaque isolates that lacked the F13L gene. Instead, the Southern blot analysis revealed the presence of a 3.7-kbp band, which is diagnostic of the single-crossover virus, as well as 1.9-and 2.6-kbp bands (Fig. 3, SC) .
The failure to isolate plaques containing only doublecrossover recombinant virus usually signifies that the target gene is essential for virus replication. Strictly speaking, however, such a result only indicates that the desired deletion mutant cannot form plaques. Since the VP37 protein is present in the EEV but not in the INV, we originally thought that the F13L deletion mutant might be impaired in EEV formation and therefore might form plaques without comets. However, the lack of success in isolating the mutant by standard means raised the possibility of a nonplaquing phenotype. Therefore, the mutant isolation protocol was altered as shown in the lower part of Fig. 2 (Fig. 3, lane C) . The IHD-J strain deletion mutant was code-named vRB10 but will be referred to here as VP37-to signify the protein that is no longer made. The K4L deletion mutant was named vRB11
and is referred to as I-K4L since the gene product has not yet been characterized.
Plaque formation by mutant viruses. The VP37-deletion mutant is unable to form plaques under standard conditions, which is 2 days at 37°C. Nevertheless, small distinct plaques could be detected with prolonged incubation. After 1 week, the mutant plaques were comparable in size to those made in 1 day by wild-type virus and considerably smaller than the standard 2-day plaques (Fig. 4) . The presence of a VP37-mutant-infected cell could be discerned in 48 h, however, as an area of high cell density. This proliferation probably resulted from the secretion of the vaccinia virus growth factor, which stimulates the growth of the surrounding uninfected cells (6) . This idea was corroborated by the formation of even more distinct foci of cell growth in A431 cells, which are highly responsive to both epidermal growth factor and vaccinia virus growth factor (6). (Fig. 5) . On the other hand, there was no significant difference in the amounts of extracellular virus produced by the K4L mutant and the parent virus (Fig. 5) .
The marked decrease in infectious virus in the medium of cells infected with the VP37-mutant could reflect either a block in formation of EEV or the release of defective particles. To discriminate between these possibilities, the infected cells were labeled with [35S]methionine and the medium was subjected to cesium chloride gradient centrifugation. The profiles obtained here (Fig. 6) (Fig. 8) . The most striking difference was the presence of numerous IHD-J particles in association with the plasma membrane and the virtual absence of such particles in cells infected with the VP37-mutant (Fig. 8 ). Higher magnifications also showed a difference, in the association of virions with intracellular Golgi membranes; we could not detect wrapped virions in VP37--infected cells (Fig. 9A ), whereas they were easily detected in IHD-J-infected cells ( Fig. 9B to E) .
Fusion from within. We tested the ability of the VP37-mutant to induce cell fusion activity in the membrane of infected cells. Polykaryons form when the pH of vaccinia virus-infected cells is lowered (8, 10, 18) . Cell fusion was induced in IHD-J-infected cells by treatment with pH 5.5 buffer (Fig. 10C) , whereas no fusion was induced by incubation at pH 7.4 (Fig. 10A) . When VP37-mutant-infected cells were subjected to either treatment, no fusion could be detected (Fig. 10B and D) . Cell fusion can also be induced with monoclonal antibody B2D10, specific for the virus HA (30) . We found this fusion to occur more slowly than low-pH-induced fusion, but it could still be easily detected in IHD-J-infected cells (Fig. lOE) . When VP37-mutant-in- fected cells were incubated in the presence of the antibody, no fusion was induced (Fig. 10F) . This difference was not a matter of timing, since no cell fusion was detected after prolonged incubation (up to 48 h) with the antibody, at which time IHD-J-infected cells had formed large syncytia (data not shown). Localization of viral HA in plasma membrane. The lack of cell fusion activity in the membranes of VP37-virusinfected cells can be explained if the proteins involved in the fusion activity were not transported properly to the plasma membrane. Accordingly, the failure of monoclonal antibody B2D1O to induce cell fusion could correlate with the absence of HA molecules in the surface of VP37--infected cells. This was not the case, however, since the presence of cell surface HA in unpermeabilized mutant-infected cells was clearly seen by immunofluorescence with monoclonal antibody B2D10 (Fig. 11) . As controls, the antibody stained the surface of unpermeabilized IHD-J-infected cells but not the surface of unpermeabilized IHD-W-infected cells, which have a mutated version of the HA that is not transported to the cell membrane (31) (Fig. liC and D) .
DISCUSSION
We isolated a novel deletion mutant of vaccinia virus that makes normal amounts of infectious INV but is defective in production of EEV. The mutant was produced by replacement of the gene encoding VP37, the major protein component of the viral outer envelope, with a selectable marker. The mutant also was defective in plaque formation, which necessitated an isolation protocol involving high-multiplicity passages of intracellular virus and limiting dilution cloning. Marker rescue confirmed that the defective plaque phenotype was due solely to deletion of the one gene. * , o @ # 6 7 . . . ' . . < . . e > -2 -r * * S @ . , ' S i a . . * m < s ; 5 F ; . ' * . § , -r ' , 5 * Our initial belief that EEV might not be required for plaque formation was based on (i) the known infectivity of INV, which has a lipoprotein envelope that can fuse with the cell membrane, (ii) the large variability in EEV production by different virus strains and the lack of correlation between plaque size and EEV yield (23) , and (iii) the ability of EEV-specific antiserum to block the cometlike spread of vaccinia virus but not plaque formation when a liquid overlay is used (2, 4) . One interpretation of those observations was that INV are primarily responsible for plaque formation by cell-to-cell spread of virus and that EEV provide the means for long-range spread. The present experiments, however, demonstrated that production of INV is not sufficient for plaque formation. The previous lack of correlation between EEV production and plaque formation could be explained if the latter is mediated by virions that are wrapped with VP37-containing Golgi-derived membranes but have not been released from the cells into the medium and therefore would not be counted as EEV. Cell-associated virions are commonly seen in electron micrographs of in-_ 5 t 'w^- fected cells. For example, the electron micrographs in Fig. 8 clearly show the presence of numerous progeny IHD-J virus particles contiguous with the outside surface of cells after removal of the medium. Significantly, however, such particles are absent from the cells infected with the VP37-deletion mutant. As we do not know whether the cellassociated enveloped virions are identical to EEV, we refer to them descriptively as CEV. The CEV appear to be in position to mediate the spread of infection to neighboring cells. Moreover, some CEV are located in intercellular spaces that would seem difficult for antibody to penetrate, perhaps accounting for the inability of EEV antisera to block plaque formation. Procedures to gently strip the CEV from the plasma membranes of infected cells are needed to compare their biochemical and physical properties with those of INV and EEV. In addition, it would be useful to determine whether the size of plaques produced by different virus strains correlates better with the amount of CEV than the amount of EEV. The direct involvement of the VP37 protein in the generation of EEV raises the question of whether the genetic differences affecting the yields of EEV produced by different virus strains are due to variations in the sequence of the VP37 proteins coded by those strains. Experiments are under way to test this possibility.
In cells infected with vaccinia virus IHD-J, it is possible to see numerous particles apparently being wrapped with Golgi membrane. No such association of particles with Golgi membrane was detected in cells infected with the VP37-deletion mutant. This is a particularly important observation since VP37 has been localized to the Golgi (12) and the wrapping is thought to be the first step in the formation of EEV (15, 19 The drug N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine inhibits virus release but does not affect the production of INV (11, 17, 24) . Although the mechanism of action of the drug is not known, it has been shown to affect EEV production, possibly at the stage of INV wrapping. The drug also affects virus spread and plaque formation in vitro,
